Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||SUMO-1 marks subdomains within glial cytoplasmic inclusions of multiple system atrophy|
|Citation:||Neuroscience Letters, 2005; 381(1-2):74-79|
|Publisher:||Elsevier Sci Ireland Ltd|
|Pountney, D.L. ; Chegini, F. ; Shen, X. ; Blumbergs, P.C. ; Gai, W.P.|
|Abstract:||Conjugation of the small ubiquitin-like modifier, SUMO-1, to target proteins is linked to the regulation of multiple cellular pathways, including nucleocytoplasmic trafficking, cell cycle progression, the ubiquitin-proteasome system and apoptosis. Recently, the accumulation of SUMOylated proteins in pathological neuronal intranuclear aggregates has been found in several neurodegenerative diseases. The aim of our study was to examine SUMO-1 in the alpha-synucleinopathy diseases, Multiple System Atrophy (MSA) and Dementia with Lewy Bodies (DLB). We conducted anti-SUMO-1 immunostaining of fixed brain tissue sections and smears of unfixed brain tissue homogenates of DLB and MSA cases. We found that oligodendroglial cytoplasmic inclusions, the alpha-synuclein-positive cytoplasmic aggregates that characterize MSA, exhibit robust punctate SUMO-1 immunostaining, marking discrete submicron-sized subdomains within the inclusion bodies. Lewy bodies in smears of DLB tissue homogenates showed similar SUMO-1-positive structures, although these were not detected in fixed tissue. In cell culture experiments, we found that the nuclear and perinuclear accumulation of SUMO-1 aggregates could be induced in glioma cells by chemical inhibition of proteasomal protein degradation.|
|Keywords:||Cerebral Cortex; Neuroglia; Inclusion Bodies; Cytoplasm; Humans; Multiple System Atrophy; Lewy Body Disease; Nerve Tissue Proteins; SUMO-1 Protein; Biological Markers; Tissue Distribution; Synucleins; alpha-Synuclein|
|Appears in Collections:||Pathology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.